BACKGROUND: Insights from neuroimaging-based biomarker research have not yet translated into clinical practice. This translational gap may stem from a focus on diagnostic classification, rather than on prediction of transdiagnostic psychiatric symptom severity. Currently, no transdiagnostic, multimodal predictive models of symptom severity that include neurobiological characteristics have emerged. METHODS: We built predictive models of 3 common symptoms in psychiatric disorders (dysregulated mood, anhedonia, and anxiety) from the Consortium for Neuropsychiatric Phenomics dataset (N = 272), which includes clinical scale assessments, resting-state functional magnetic resonance imaging (MRI), and structural MRI measures from patients with schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder and healthy control subjects. We used an efficient, data-driven feature selection approach to identify the most predictive features from these high-dimensional data. RESULTS: This approach optimized modeling and explained 65% to 90% of variance across the 3 symptom domains, compared to 22% without using the feature selection approach. The top performing multimodal models retained a high level of interpretability that enabled several clinical and scientific insights. First, to our surprise, structural features did not substantially contribute to the predictive strength of these models. Second, the Temperament and Character Inventory scale emerged as a highly important predictor of symptom variation across diagnoses. Third, predictive resting-state functional MRI connectivity features were widely distributed across many intrinsic resting-state networks. CONCLUSIONS: Combining resting-state functional MRI with select questions from clinical scales enabled high prediction of symptom severity across diagnostically distinct patient groups and revealed that connectivity measures beyond a few intrinsic resting-state networks may carry relevant information for symptom severity.
BACKGROUND: Insights from neuroimaging-based biomarker research have not yet translated into clinical practice. This translational gap may stem from a focus on diagnostic classification, rather than on prediction of transdiagnostic psychiatric symptom severity. Currently, no transdiagnostic, multimodal predictive models of symptom severity that include neurobiological characteristics have emerged. METHODS: We built predictive models of 3 common symptoms in psychiatric disorders (dysregulated mood, anhedonia, and anxiety) from the Consortium for Neuropsychiatric Phenomics dataset (N = 272), which includes clinical scale assessments, resting-state functional magnetic resonance imaging (MRI), and structural MRI measures from patients with schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder and healthy control subjects. We used an efficient, data-driven feature selection approach to identify the most predictive features from these high-dimensional data. RESULTS: This approach optimized modeling and explained 65% to 90% of variance across the 3 symptom domains, compared to 22% without using the feature selection approach. The top performing multimodal models retained a high level of interpretability that enabled several clinical and scientific insights. First, to our surprise, structural features did not substantially contribute to the predictive strength of these models. Second, the Temperament and Character Inventory scale emerged as a highly important predictor of symptom variation across diagnoses. Third, predictive resting-state functional MRI connectivity features were widely distributed across many intrinsic resting-state networks. CONCLUSIONS: Combining resting-state functional MRI with select questions from clinical scales enabled high prediction of symptom severity across diagnostically distinct patient groups and revealed that connectivity measures beyond a few intrinsic resting-state networks may carry relevant information for symptom severity.
Authors: Victoria B Risbrough; Dewleen G Baker; Daniel M Stout; Alan N Simmons; Caroline M Nievergelt; Arpi Minassian; Nilima Biswas; Adam X Maihofer Journal: Neuropsychopharmacology Date: 2022-03-28 Impact factor: 8.294